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Purpose: The purpose of the present study was to
investigate whether electrical stimulation (ES) improves the
paralytic effect of botulinum toxin type A (BTX-A) and
evaluate the differences between low frequency (LF) and
high frequency (HF) ES in children with spastic diplegic
cerebral palsy (CP). Materials and Methods: Twenty-three
children with spastic diplegia CP who had BTX-A injections
into both gastrocnemius muscles were assessed. Following
the toxin injection, electrical stimulation was given to 1 side
of the injected muscles and a sham-stimulation to the other
side for 30 min a day for 7 consecutive days [HFES (25 Hz)
to 11 children, LFES (4 Hz) to 12 children]. The compound
motor action potentials (CMAP) from the gastrocnemius
muscle were assessed before injection and at 5 time points
(days 3, 7, 14, 21, and 30) after injection. The clinical
assessments of spasticity were performed before and 30 days
after injection. Results: The CMAP area became significantly
lower in both LFES and HFES sides from 3 days after
injection compared to baseline values. In other words, the
CMAP area of the sham-stimulated side showed a significant
decrease at 7 or 14 days after injection. However, there were
no significant differences in clinical assessment of spasticity
between the stimulated and sham-stimulated sides. Conclusion:
Short-term ES in both LF and HF to the spastic muscles
injected with BTX-A might induce earlier denervating action
of BTX-A. However, it does not necessarily lead to clinical
and electrophysiological benefits in terms of reduction of
spasticity.
Key Words: Botulinum toxin type A, electrical stimulation,
cerebral palsy, spasticity
INTRODUCTION
The spastic type is the most common form of
CP.
1,2 Spasticity has been considered to be a main
contributor to both the impairment of function
and decreased longitudinal muscle growth in
children with spastic CP, which can lead to
deformity.
3-7 Thus, reduction of spasticity in
children with CP is important in the management
of the disease. Several treatment options have
been used to reduce the spasticity and to improve
function in children with CP. Among them,
BTX-A injection has become a popular treatment
for spasticity in the absence of fixed deformities
in the pediatric population. Furthermore, the use
of BTX-A is considered to be an effective and safe
treatment for spasticity or dystonia.
8
BTX-A produces a dose-dependent reversible
chemodenervation of the injected muscle by
blocking the presynaptic release of acetylcholine
at the neuromuscular junction.
9 Denervation of the
spastic muscle allows muscle growth, prevention
of contracture, and diminution of dynamic
deformity. However, treatment is not always
successful and the effects are often transient.
Furthermore, variable clinical responses can be
observed in patients with the same form of the
disease.
10,11
Since Hughes and Whaler
12 in 1962 demonstrated
that the repetitive ES of the axon increased BTX-A
absorption in a frog diaphragm preparation
model, it has been suggested that muscle activity
may affect the paralytic effect of BTX-A. In recent
experimental studies, performing a post-injection
stretching exercise with ES was beneficial for
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maximizing the muscle paralysis effect of BTX-A
on calf muscles in rabbits.
13 Also, in normal
human muscles, the effect of BTX-A on the muscle
can be increased by ES immediately after
injection.
10,14 However, it remains unclear for
spastic human muscle whether muscle activity
induced by ES increases the effect of BTX-A on
spasticity and functional improvement of
patients.
11,15,16
We designed this study to investigate whether
ES improves the paralytic and anti-spastic effects
of BTX-A and evaluate the differences between
LF- and HFES in children with spastic CP using
electrophysiological and clinical examination.
MATERIALS AND METHODS
Subjects
Among children with spastic CP who were
admitted to our rehabilitation hospital, those who
were planning to have BTX-A injections into both
gastrocnemius muscles were included in this
study. Exclusion criteria included previous ortho-
pedic surgery, previous BTX-A injection within
the past 12 months, and fixed joint contractures.
This study was approved by the Institutional
Review Board of our institution, and informed
consent was obtained from the parents of children.
Twenty-three children (12 girls, 11 boys) parti-
cipated in the study. The mean age was 46.0 ± 18.1
months. The types of CP included patients who
were diplegic (n = 18) and quadriplegic (n = 5).
The gross motor functional level of each patient
was determined by the Gross Motor Function
Classification System (GMFCS).
17 They were
classified as follows: 3 were considered level I
(13%), 5 level II (22%), 8 level III (35%), and 7 level
IV (30%). The physical and occupational therapy
program was carried out during the hospital stay
and included 6 sessions of physical therapy and
6 sessions of occupational therapy per week (30
minutes each per session).
BTX-A injection and ES
A lignocaine-based local anesthetic, EMLA
cream (Astra, Kings Langley, UK), was applied to
the skin prior to BTX-A injection. One hundred
units of BTX-A (Botox, Allergan Inc., CA, USA)
was diluted with 2 mL of 0.9% saline, and the
same doses of the toxin were injected into the
right and left gastrocnemius muscles (4 - 5 units/
kg in each muscle).
Following the toxin injection, ES was given to
1 side of injected muscles and a sham stimulation
was administered to the other side for 30 minutes
a day for 7 consecutive days. The children were
randomly assigned into 2 groups: 11 children (age,
40.2 ± 14.0 months) were assigned to the HFES (25
Hz) group, and 12 (age, 52.5 ± 20.4 months) to the
LFES (4 Hz) group. Pairs of 90 × 50 mm self-
adhesive surface electrodes (ValuTrode, Axelgaard
Co., CA, USA) were attached close to a motor
point. A 4-channel device (MegaXP, CyberMedic
Corp., Iksan, Korea) with continuous trains of
biphasic rectangular symmetric 0.25 ms current
pulses was used for stimulation. The stimulation
intensity was adjusted at threshold intensity for
minimal gastrocnemius muscle twitching.
Electrophysiological assessment
In each gastrocnemius muscle, we used Synergy
II (VIASYS Healthcare Inc., Madison, USA) to
record the CMAP evoked by supramaximal ES of
the tibial nerve at the popliteal area. The recording
bandwidth was 3 - 10,000 Hz. CMAP was recorded
with a self-adhesive electrode (Neuroline 710,
Ambu A/S, Ballerup, Denmark). The active
recording electrode was placed at mid-belly of the
medial gastrocnemius muscle near the motor
point. A reference electrode was placed at the
Achilles tendon, and a ground electrode was
placed between an active recording electrode and
stimulator.
18 The CMAPs from the gastrocnemius
muscle were assessed before injection and at 5
discrete time points (days 3, 7, 14, 21, and 30) after
injection. The attachment points of the active
electrode were marked with an oil pen to ensure
accurate recording of the CMAP at the same
location at every time point. Peak-to-peak
amplitude and the area of the CMAP were
measured. The amplitude changes of CMAP
(Amplitude %) and the area changes of CMAP
(Area %) were analyzed.Electrical Stimulation After BTX-A Injection
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Clinical assessment
The same investigator, who was blind to the
treatment regimen, performed the clinical
examination before the injection and at 30 days
after injection. The triceps surae muscle tone was
assessed using the Modified Ashworth Scale and
Modified Tardieu Scale.
19 The Modified Ashworth
Scale is a 6-point rating scale used to gauge
muscle resistance to passive movement. The
scoring was as follows: 0 = no increase in muscle
tone; 1 = slight increase in muscle tone as
manifested by a "catch and release" or minimal
resistance at the end of the range of motion; 2 =
slight increase in muscle tone shown as a "catch"
and followed by minimal resistance throughout
less than half the range of motion; 3 = marked
increase in muscle tone through most of the range
of motion, the affected part being easily moved;
4 = considerable increase in muscle tone and
difficult passive movement; 5 = affected part
remained rigid. Two angles (R1 and R2) were
determined in the Modified Tardieu Scale. The
angle of muscle reaction (R1) was defined as the
point in the joint range in which a velocity-
dependent "catch" or clonus was felt during a
quick stretch of the muscle. The angle of full
range of motion (R2) was equivalent to the
passive range of motion. Both R1 and R2 were
measured relative to the neutral position of the
ankle joints. The neutral position at the ankle joint
(corresponding to angle zero) was the position
with the ankle at 90 degrees to the lower leg. A
negative value would be given if the ankle could
not be dorsiflexed beyond angle zero. Modified
Ashworth Scale and Modified Tardieu Scale were
measured in both the knee flexion and extension
positions.
Statistical analysis
To determine statistical differences between
stimulated and sham-stimulated sides, Wilcoxon-
signed rank test was used. To compare the
post-injection value of CMAP at each time point
to the pre-injection value for analyzing the onset
of paralyzing effect, repeated measures ANOVA
was used after performing normality test by
Shapiro-Wilk test. Data for patients in the LFES
and HFES groups were tested separately.
We used Mann-Whitney test to compare the
Amplitude % and Area % of stimulated sides of
the LFES and HFES groups at each time points.




In the LFES group, Amplitude % decreased
significantly from 7 days post-injection in both the
stimulated and sham-stimulated side when
compared to the pre-injection value of CMAP
(Fig. 1A) (p < 0.05). In contrast, Area % decreased
significantly from 3 days post-injection in the
stimulated side and from 14 days post-injection in
the sham-stimulated side, and remained low until
30 days after injection (Fig. 1B) (p < 0.05). However,
there was no significant difference in Amplitude
% and Area % between the stimulated and sham-
stimulated sides at all 6 time points.
In the HFES group, Amplitude % decreased
significantly from 7 days post-injection in the
stimulated side and from 14 days post-injection in
the sham-stimulated side, and remained low until
30 days after injection when compared to the
pre-injection value of CMAP (Fig. 2A) (p < 0.05).
Area % decreased significantly from 3 days
post-injection in the stimulated side and from 7
days post-injection in the sham-stimulated side,
and remained low until 30 days after injection
(Fig. 2B) (p < 0.05). However, there was no
significant difference in Amplitude % and Area %
between the stimulated and sham-stimulated
sides at all 6 time points.
In addition, there were no significant differ-
ences in electrophysiological parameters assessed
between the LFES and HFES groups.
Clinical assessment
In the LFES group, Modified Ashworth Scale of
ankle plantar-flexors in knee extension position,
R1 in both knee flexion and extension positions,
and R2-R1 in both knee flexion and extension
positions improved in both the stimulated andDong-wook Rha, et al.
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sham-stimulated sides at 30 days post-injection
(Table 1) (p < 0.05). However, there was no
significant difference in improvement of spasticity
between the stimulated and sham-stimulated
sides.
In the HFES group, Modified Ashworth Scale of
ankle plantar-flexors in knee extension position,
R1 in both knee flexion and extension positions,
and R2-R1 in both knee flexion and extension
positions also improved in both the stimulated
and sham-stimulated sides at 30 days post-
injection (Table 2) (p < 0.05). However, there was
also no significant difference in improvement of
spasticity between the stimulated and sham-
stimulated sides.
In addition, there were no significant differ-
ences in the clinical parameters for spasticity
between the LFES and HFES groups.
DISCUSSION
BTX-A has complex protein structures con-
taining 150 kDa neurotoxin molecule. It binds to
specific external high-affinity receptors on the
membranes of cholinergic neurons and is inter-
nalized by endocytosis into vesicular compart-
ments.
20 In order to be active, the 150 kDa
neurotoxins must be nicked by proteases into 2
polypeptide fragments; a 100 kDa heavy chain
and 50 kDa light chain that are held together by
an inter-chain disulfide bond.
21 The light chain,
which is translocated across the endosomal
membrane into the cytosol, is a zinc-endopeptidase
Fig. 2. Comparison of amplitude and area of compound motor action potential between the 25 Hz frequency stimulated
side and sham-stimulated side of gastrocnemius muscles in children with spastic CP (n = 11). *p < 0.05, before injection
vs. each time point after injection.
Fig. 1. Comparison of amplitude and area of compound motor action potential between the 4 Hz frequency stimulated
side and sham-stimulated side of gastrocnemius muscles in children with spastic CP (n = 12). *p < 0.05, before injection
vs. each time point after injection.
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responsible for intracellular toxin activity.
20 In
animal experiments, it is suggested that muscle
inactivity may delay this activation process of
BTX-A while ES influences the uptake and onset
latency. Hughes and Whaler
12 demonstrated that
repetitive ES of the axon increased BTX-A absorp-
tion in a frog diaphragm preparation model, and
Simpson
22 identified that ES accelerates the lytic
step for internalization of BTX-A into the motor
nerve terminal, thereby facilitating its inhibitory
effect on acetylcholine release.
In human muscles, some researchers tried to
clarify the effectiveness of ES applied to muscles
following BTX-A injection using neurophysiologic
quantification with nerve conduction studies.
10,13,
14,18 Eleopra et al.
10 injected low dose BTX-A into
Table 1. Comparison of Clinical Assessment Data between 4 Hz Frequency-Stimulated Side and Non-stimulated
Side of Gastrocnemius Muscles in Children with Spastic Cerebral Palsy (n = 12)
Stimulated side Non-stimulated side
Pre-injection Post-injection 30 days Pre-injection Post-injection 30 days
MAS Knee flexion 2.3 ± 0.6 2.0 ± 0.1 2.2 ± 0.4 1.9 ± 0.3
Knee extension 2.7 ± 0.8 2.2 ± 0.4* 2.8 ± 0.8 2.2 ± 0.4*
MTS R1 (Knee flexion) - 17.5 ± 9.4 - 7.1 ± 8.4* - 17.1 ± 8.6 - 7.9 ± 6.6*
R1 (Knee extension) - 27.1 ± 8.6 - 15.0 ± 10.4* - 27.1 ± 5.8 - 16.7 ± 7.2*
R2 (Knee flexion) 35.8 ± 7.0 35.0 ± 5.2 35.0 ± 6.4 34.2 ± 4.7
R2 (Knee extension) 17.9 ± 5.4 21.3 ± 4.8 19.2 ± 5.6 22.5 ± 5.0
R2-R1 (Knee flexion) 53.3 ± 9.8 42.1 ± 8.6* 52.1 ± 10.1 42.1 ± 6.9*
R2-R1 (Knee extension) 45.0 ± 8.0 36.3 ± 7.7* 46.3 ± 5.3 39.2 ± 6.7*
MAS, modified ashworth scale; MTS, modified tardieu scale; R1, angle of muscle reaction; R2, angle of full range of motion.
Values are means ± standard deviation.
*p < 0.05 when compared between pre-injection and post-injection 30 days data.
Table 2. Comparison of Clinical Assessment Data between 25 Hz Frequency-Stimulated Side and Non-stimulated
Side of Gastrocnemius Muscles in Children with Spastic Cerebral Palsy (n = 11)
Stimulated side Non-stimulated side
Pre-injection Post-injection 30 days Pre-injection Post-injection 30 days
MAS Knee flexion 2.1 ± 0.1 2.0 ± 0.0 2.0 ± 0.4 1.8 ± 0.4
Knee extension 2.5 ± 0.5 2.0 ± 0.5* 2.5 ± 0.5 2.1 ± 0.5*
MTS R1 (Knee flexion) - 11.4 ± 7.8 - 4.6 ± 6.5* - 11.4 ± 9.0 - 2.7 ± 7.5*
R1 (Knee extension) - 23.6 ± 9.2 - 12.3 ± 7.9* - 23.6 ± 9.2 - 11.8 ± 7.5*
R2 (Knee flexion) 30.9 ± 6.3 30.9 ± 4.9 31.8 ± 8.7 32.7 ± 6.1
R2 (Knee extension) 19.1 ± 5.8 19.1 ± 8.0 18.6 ± 6.7 19.1 ± 7.0
R2-R1 (Knee flexion) 42.3 ± 9.3 35.5 ± 8.2* 43.2 ± 10.8 35.5 ± 7.6*
R2-R1 (Knee extension) 42.7 ± 9.0 31.4 ± 5.5* 42.3 ± 9.8 30.9 ± 6.3*
MAS, modified ashworth scale; MTS, modified tardieu scale; R1, angle of muscle reaction; R2, angle of full range of motion.
Values are means ± standard deviation.
*p < 0.05 when compared between pre-injection and post-injection 30 days data.Dong-wook Rha, et al.
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normal adult extensor digitorum brevis muscles
and delivered the electrical current to the injected
muscles at a 4 Hz frequency. They compared the
Amplitude % of CMAP-which was the parameter
we also used in this study-and reported that the
effect of the induced neuromuscular blockade was
significantly greater in the electrically stimulated
side. Flasson et al.
14 also reported that the short-
term ES to the injected muscles induces a rapid
and persistent reduction of CMAP recorded at the
extensor digitorum brevis muscles in patients
with spastic paraplegia. However, the extensor
digitorum brevis muscles at which they assessed
the changes of CMAP in both studies are not the
sites where the BTX-A injections are usually
performed in clinical practice; the gastrocnemius
muscles are the muscles most commonly treated
with BTX-A injection in children with spastic CP.
For that reason, we selected the gastrocnemius
muscles to assess the CMAP. Short-term ES was
given only to these gastrocnemius muscles to find
out the effect of ES on the injected muscle. In this
study, a decrease in Area % of CMAP became
significant from 3 days post-injection on the
stimulated side and 7 or 14 days on the sham-
stimulated side in both the LFES and HFES
groups. These findings suggest that ES might
induce the earlier denervating action of BTX-A on
the gastrocnemius muscles for correcting the
equinus deformity in children with spastic CP.
This earlier onset of denervation can be explained
by the foregoing mechanism; ES facilitates the
lytic step of BTX-A for internalization. Although
the onset of decrease in the CMAP area is
shortened in the stimulated sides, there was no
significant difference in Amplitude % and Area %
between the stimulated and sham-stimulated
sides at all 6 time points in both the LFES and
HFES groups. In addition, decrease in amplitude
% of CMAP became significant from post-injection
7 days in both the stimulated and sham-
stimulated sides of the LFES group. Therefore, it
is not appropriate to state that the combined
treatment of BTX-A and ES is superior to BTX-A
alone in electrophysiological analysis.
It is known that the effects of ES can be
modulated by changing the stimulation fre-
quency.
23,24 In the study by Frasson et al.
14 to
measure CMAP at extensor digitorum brevis
muscles after BTX-A injection and ES, 2 stimula-
tion frequencies (LF, 4 Hz; and HF, 25 Hz) were
used, and they reported that Amplitude % of
CMAP was significantly lower on the 4 Hz
stimulated side than on the non-stimulated side 4
days after injection, and it remained until 60 days
after injection. Conversely, in patients receiving 25
Hz ES, no significant difference was found between
the stimulated and non-stimulated muscle. The
above authors suggested that prolonged HFES
could reduce the excitability at the site of nerve
fiber stimulation, and this might be associated
with the frequency-dependent effects of ES. In our
findings, the CMAP area of the gastrocnemius
showed that both 4 and 25 Hz of stimulation
hastened the onset of denervation induced by
BTX-A compared to the sham-stimulated side.
Additionally, there were no significant differences
in the electrophysiological parameters assessed
between the LFES and HFES groups. The reasons
why our study did not show frequency-dependent
changes and did not accord with previous
observations remain unexplained. However, in the
study by Frasson et al.,
14 they also found
spontaneous denervation potentials appearing
early in needle electromyographic examination of
extensor digitorum brevis muscles at both stimu-
lation frequencies. As a result, they acknowledged
that they could not explain why ES in their study
induced frequency-dependent changes. Therefore,
further research is needed to clarify whether
various stimulation frequencies used could
differentially affect the absorption of BTX-A.
Several studies have been performed to
investigate whether additional ES enhances the
clinical outcome after BTX-A injection therapy.
Hesse and colleagues11 reported that ES of the
lower limb muscles following BTX-A injection
resulted in greater improvement of gait velocity
and a reduction of muscle tone in randomized
controlled studies of patients with spastic
hemiplegia after stroke. For the upper limb of
hemiplegic patients after stroke, they reported
that ES reduced the muscle tone of the elbow joint
and improved the cleaning activity of the affected
palm.
16 However, in their studies, they applied ES
not only to the injected muscles but also to
antagonist muscles. When ES is applied to
antagonist muscle, it has an inhibitory effect onElectrical Stimulation After BTX-A Injection
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the activity of the injected muscle through the
polysynaptic inhibiting pathway, reducing its
spasticity.
25 In addition, it may have a positive
action on the rheological properties through
stretching of the injected muscles.
26 Stretching the
spastic muscles after BTX-A injection has been
utilized to enhance the effect of BTX-A.
10,13,27 It is
hypothesized that the prolonged stretching of a
muscle could result in a greater internalization of
BTX-A or microstructural modifications of the
muscles, which reduces the spasticity.
26 A recent
study showed that optimal stretching with taping
could lead to higher and faster hypertonus reduc-
tion compared to ES to the injected muscles and
splinting.
26 From this prospective, the beneficial
effect of electrical simulation in these studies may
be the consequence of the effect of ES on the
antagonist to an injected muscle or the effect of ES
on both the antagonist and injected muscles. As
for children with CP, only 1 study on the effect
of ES on the clinical outcome following BTX-A
injection has been carried out by Detrembleur et
al.
15 They applied ES only to the injected muscles
and used relatively HF current pulses (20 Hz) for
stimulation, and used 3-dimensional gait analysis
and clinical assessment data including passive
joint range of motion, Modified Ashworth Scale,
and physician rating scale without electrophysio-
logical assessment. The result showed no evidence
of superiority of the addition of ES to the BTX-A
injection therapy. For clinical assessment of
spasticity of the triceps surae muscle, we used
Modified Ashworth Scale and Modified Tardieu
Scale. Modified Ashworth Scale is the most
commonly used clinical scale for the measurement
of spasticity. However, their validity has recently
been questioned because they do not address the
velocity-dependent aspect of the phenomenon of
spasticity.
28 On the other hand, Modified Tardieu
Scale measures the passive range of movement at
different movement velocity (slow and fast velocity
passive stretches) and determines the dynamic
component of the muscle contracture.
29 Therefore,
this scale has been suggested as a more suitable
tool for spasticity measurement compared to
Modified Ashworth Scale.
30,31 In our findings, both
scales for clinical assessment of spasticity did not
differ between the stimulated and sham-stimu-
lated sides in both the LFES and HFES groups
before and 30 days after BTX-A injection. Because
we did not investigate earlier changes of spasticity
before 30 days post-injection, we could not
ascertain whether reduction of spasticity was
induced more rapidly in the stimulated sides.
However, it is difficult in our clinical analysis to
establish superiority of the combined treatment of
BTX-A and ES over BTX-A alone.
In conclusion, the results of this study sug-
gested that short-term ES in both LF and HF to
spastic muscles after BTX-A injection might
induce the earlier response of BTX-A. However,
there was no definite evidence in this study that
the adjuvant ES after BTX-A injection was
superior to BTX-A alone in alleviating spasticity
in terms of both electrophysiological and clinical
assessment.
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